Opendata, web and dolomites

MaxONCO SIGNED

A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MaxONCO project word cloud

Explore the words cloud of the MaxONCO project. It provides you a very rough idea of what is the project "MaxONCO" about.

650    survived    initiated    immuno    immunotherapy    develops    acting    salivary    positive    antigens    plans    drug    primary    private    anywhere    maxonco    track    limited    diagnosed    benefit    situ    grow    agent    drugs    switzerland    prepare    initial    radiotherapy    head    globally    standard    rate    sme    compare    therapy    accounting    cells    spine    designation    shown    swissmedic    45    biotech    indication    chordoma    breakthrough    autologous    ind    first    approved    modified    treat    commercialization    mouth    trials    encouraging    approval    sites    occurs    types    maxivax    opportunity    boost    neck    investigational    perform    besides    time    profile    base    showing    skull    care    treatment    swiss    employees    genetically    cancer    throat    rare    biological    patients    cancers    immune    efficacy    trial    benign    surgery    clinical    2018    indications    vaccine    showed    data    market    25    safety    company    indirect    stage    fast    line    released    source    orphan    jobs    point    usa    glands    group    cell    fda   

Project "MaxONCO" data sheet

The following table provides information about the project.

Coordinator
MAXIVAX SA 

Organization address
address: RUE DE LATHEENEE 24
city: GENEVA
postcode: 1206
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 3˙979˙000 €
 EC max contribution 2˙785˙300 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAXIVAX SA CH (GENEVA) coordinator 2˙785˙300.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

MaxiVAX a private Swiss clinical-stage biotech company with a novel cancer immunotherapy product in development (MaxONCO) will perform two Phase 2 clinical trials in two indications (Head & Neck, and Chordoma) and prepare the commercialization of MaxONCO, its first immuno-therapy product. The objective of the Phase II clinical trials is to demonstrate efficacy and safety of MaxONCO in the patients treated and compare the results to the current standard of care. MaxONCO is a biological product acting as a cancer vaccine and composed of (i) an immune boost agent released in situ by a genetically modified cell line and (ii) cancer autologous cells, which are the source of antigens. A Phase 1 trial in 25 patients with a range of cancer types at an advanced stage showed encouraging efficacy data and a benign safety profile of the treatment. Head and Neck cancer is a group of cancers that develops in the areas of the head and neck which include the mouth, throat and salivary glands; accounting for 650,000 new cases in 2018 diagnosed globally. With the approval of Swissmedic, MaxiVAX has initiated the Phase 2 clinical trial to evaluate MaxONCO in 40-45 patients with Head & Neck cancer. The study will be conducted across 4-6 different sites in Switzerland. Encouraging clinical results show that among 4 initial Head & Neck patients treated with MaxONCO all survived beyond the 6-month time point (primary efficacy end point). Chordoma is a rare type of cancer that occurs in the skull base and anywhere along the spine. Besides surgery and radiotherapy that are showing only limited success, there are currently no approved drugs to treat Chordoma. In the Phase 1 clinical trial, MaxONCO, has shown promising effects on chordoma patients. A phase 2 Chordoma clinical trial will be conducted in the EU and USA, under an FDA investigational new drug application (IND). A positive overall response rate in Chordoma would allow MaxONCO to benefit from the breakthrough therapy designation as fast-track market opportunity, Chordoma being an orphan indication. Currently accounting for 8 employees, the company plans to grow up to 25 employees by the end of the SME phase 2 project, creating up to 30 indirect jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAXONCO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAXONCO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

MycoProScale (2020)

MycoProScale – Creating global markets with a unique large-scale Mycorrhiza production method

Read More